Navigation Links
Micromet Demonstrates That the Antibodies in Commercial Products Herceptin, Erbitux, Vectibix and Xolair Can Be Converted Into Highly Potent, T Cell- Engaging BiTE Antibodies
Date:4/14/2008

the BiTE antibody platform, we can teach conventional monoclonal antibodies how to recruit T cells for a very selective and highly effective lysis of target cells. Proof of concept has been established for the BiTE platform by MT103/MEDI-538, which has shown clinical responses in relapsed and refractory non-Hodgkin's lymphoma patients."

Reference

(1) Lutterbuese, R. et al. Conversion of Cetuximab and Trastuzumab into

T Cell-engaging BiTE Antibodies Creates Novel Drug Candidates with

Superior Anti-tumor Activity. Annual Meeting of AACR, San Diego, 2008,

Abstract No. 2402.

About BiTE Antibodies

BiTE(R) antibodies are designed to direct the body's cytotoxic, or cell- destroying, T cells against tumor cells, and represent a new therapeutic approach to cancer therapy. BiTE antibodies have been shown to induce an immunological synapse between a T cell and a tumor cell in the same manner as observed during physiological T cell attacks. These cytolytic synapses enable the delivery of cytotoxic proteins from T cells into tumor cells, ultimately inducing a self-destruction process in the tumor cell referred to as apoptosis, or programmed cell death. In the presence of BiTE antibodies, T cells have been demonstrated to serially eliminate tumor cells, which explains the activity of BiTE antibodies at very low concentrations and at very low ratios of T cells to target cells. Through the process of killing cancer cells, T cells proliferate, which leads to an increased number of T cells at the site of attack.

Several antibodies in Micromet's product pipeline are BiTE antibodies and have been generated based on Micromet's proprietary BiTE antibody platform. The most advanced BiTE antibody is MT103 (MEDI-538), targeting CD19, and has provided proof-of-concept in an ongoing phase 1 clinical study in patients with advanced non-Hodgkin's lymphoma. MT110, which is targeting EpCAM (CD326) and is the first BiTE antibod
'/>"/>

SOURCE Micromet, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related medicine technology :

1. Micromet Announces Presentation of Five Posters Related to Its Proprietary BiTE Antibody Platform at Annual Meeting of American Association for Cancer Research
2. Micromet Announces the Publication of BiTE Antibody Review in Drugs of the Future
3. Micromet Announces Changes in Management Team
4. BSI-201 Demonstrates Significant Tumor Growth Inhibition and Increased Survival Rates in Preclinical Ovarian Cancer Studies
5. Poniard Pharmaceuticals Oral Picoplatin Demonstrates Positive Bioavailability in Ongoing Phase 1 Trial
6. CorMatrix(R) Announces Intramyocardial Injection of Emulsified ECM Technology(TM) Demonstrates Enhanced Angiogenesis and Improved Cardiac Function in a Preclinical Model
7. TAXUS(R) Stent Demonstrates Similar Outcomes in Diabetic Patients Compared to Non-diabetics in Pooled Analysis of TAXUS IV and V Trials
8. Landmark ONTARGET(TM) Trial Demonstrates Micardis(R) is Equally Effective as Ramipril, with Fewer Discontinuations, in a Broad High-Risk Cardiovascular Population
9. Abbotts XIENCE(TM) V Drug Eluting Stent Demonstrates Consistent and Positive Clinical Outcomes Out to Two Years
10. ANX-201 Demonstrates a Unique Resistance Profile in Preclinical Tests
11. GSK Cervical Cancer Candidate Vaccine CERVARIX (R) Demonstrates Long-Term Protection for More Than Six Years
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/15/2014)... 15, 2014 Reportlinker.com announces that a ... its catalogue: PharmaPoint: ... Market Analysis to 2022 ... - India Drug Forecast and Market Analysis ...
(Date:1/15/2014)... , Jan. 15, 2014 Reportlinker.com ... report is available in its catalogue: ... and Technologies for Advanced Drug Delivery ... Administration http://www.reportlinker.com/p01941928/Global-Markets-and-Technologies-for-Advanced-Drug-Delivery-Systems----Focus-on-Routes-of-Administration.html#utm_source=prnewswire&utm_medium=pr&utm_campaign=Drug_Delivery_Technology ...
(Date:1/14/2014)... Mass. , Jan. 14, 2014 HeartWare ... leading innovator of less invasive, miniaturized circulatory support technologies ... today announced that it expects revenues for the fourth ... expected full-year 2013 revenues to approximately $208 million. ...
Breaking Medicine Technology:PharmaPoint: Atopic Dermatitis - India Drug Forecast and Market Analysis to 2022 2PharmaPoint: Atopic Dermatitis - India Drug Forecast and Market Analysis to 2022 3PharmaPoint: Atopic Dermatitis - India Drug Forecast and Market Analysis to 2022 4PharmaPoint: Atopic Dermatitis - India Drug Forecast and Market Analysis to 2022 5Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on Routes of Administration 2Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on Routes of Administration 3Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on Routes of Administration 4Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on Routes of Administration 5Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on Routes of Administration 6Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on Routes of Administration 7Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on Routes of Administration 8Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on Routes of Administration 9Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on Routes of Administration 10Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on Routes of Administration 11Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on Routes of Administration 12Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on Routes of Administration 13Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on Routes of Administration 14Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on Routes of Administration 15Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on Routes of Administration 16HeartWare International Announces Preliminary Fourth Quarter 2013 Revenues 2HeartWare International Announces Preliminary Fourth Quarter 2013 Revenues 3HeartWare International Announces Preliminary Fourth Quarter 2013 Revenues 4
... TRIANGLE PARK, N.C., Jan. 6, 2011 CeNeRx BioPharma, Inc., today ... new formulation of TriRima ™, the company,s novel antidepressant in ... it will be presenting at Biotech Showcase™ ... 11:00 AM PST. TriRima is a member ...
... Pharmasset, Inc. (Nasdaq: VRUS ), announced today positive ... HCV genotype 2 or 3 (GT2/3) arm of the PSI-7977 Phase ... dual nucleotide study.   Pipeline Update and ... PSI-7977 in combination with pegylated interferon and ribavirin (Peg-IFN/RBV) in a ...
Cached Medicine Technology:CeNeRx Initiates Phase II Trial of TriRima™ as Monotherapy in Treatment Resistant Depression 2CeNeRx Initiates Phase II Trial of TriRima™ as Monotherapy in Treatment Resistant Depression 3Pharmasset Reports Positive Results from its HCV Clinical Programs 2Pharmasset Reports Positive Results from its HCV Clinical Programs 3Pharmasset Reports Positive Results from its HCV Clinical Programs 4Pharmasset Reports Positive Results from its HCV Clinical Programs 5Pharmasset Reports Positive Results from its HCV Clinical Programs 6
(Date:4/23/2014)... Oncotarget , explored tumour heterogeneity where different ... signatures within the same cancer. Such differences could ... strategies. , Firstly they confirmed the mutual exclusivity ... or BRAF mutation. Secondly, they found that lung ... that specific mutation present uniformly throughout the tumour, ...
(Date:4/23/2014)... bottom of Alzheimer,s disease has been a rapidly ... In the latest crook in the research road, ... interaction between proteins associated with the disease. The ... Chemical Neuroscience , could have important implications for ... Nieznanski and colleagues explain that for years, research ...
(Date:4/22/2014)... (Chicago) A recently FDA-approved device has been shown ... as much as 50 percent. When coupled with an ... Rush, the device facilitated the complete elimination of seizures ... in the decade-long clinical trials. , That,s good news ... in the U.S. living with epilepsy whose seizures can,t ...
(Date:4/22/2014)... April 22, 2014 Researchers at UT Southwestern Medical ... from depression . , A team of ... by which ghrelin (a hormone with natural anti-depressant properties) ... potentially powerful new treatment for depression in the form ... The study, published online in April,s issue of ...
(Date:4/22/2014)... Bethesda, MD, April 22, 2014: The Association for ... The Journal of Molecular Diagnostics on ... the baccalaureate and master,s levels of education. The ... (MLS) Curriculum Task Force of the AMP Training ... the critical need of educating future medical laboratory ...
Breaking Medicine News(10 mins):Health News:Non-uniform genetic mutations identified in lung cancers could lead to targeted treatment 2Health News:Newly approved brain stimulator offers hope for individuals with uncontrolled epilepsy 2Health News:Depressed? Researchers identify new anti-depressant mechanisms, therapeutic approaches 2Health News:Depressed? Researchers identify new anti-depressant mechanisms, therapeutic approaches 3Health News:AMP publishes curriculum recommendations for medical laboratory scientists 2
... blood vessel walls can vary among individuals depending on factors ... research at UC Davis. The new research reinforces the ... linings that can lead to heart disease and strokes. ... cholesterol," known to increase risk of inflammation of the endothelium, ...
... Salamon HealthDay Reporter , THURSDAY, Feb. 17 (HealthDay ... weeks early has no discernible impact on babies, a new ... than their full-term peers and those delays may affect their ... term and 1,200 late preterm infants -- those born between ...
... 2011) Two studies published in the current issue ... islet cell transplantation for treating diabetes. Researchers in Milan, ... in diabetic therapy and islet cell regeneration and Canadian ... in vitro. Both studies are in the ...
... Feb. 17 (HealthDay News) -- The area of the brain ... that suggests the brain is a "task machine" instead of ... brain scans, the researchers measured neural activity in eight blind ... blind since birth, showed activity in the exact same part ...
... cell phone use does not appear to increase the ... a study by University of Manchester scientists suggests. ... Office of National Statistics to look at trends in ... 1998 and 2007. The study, published in the ...
... urban public housing spend more time playing outdoors than ... Columbia University and Princeton University. Contrary to ... living in poorer circumstances would be playing outside less, ... played outside 13 percent more per day, on average, ...
Cached Medicine News:Health News:Study reinforces link between obesity, high-fat meals and heart disease 2Health News:Delivery Even a Bit Early May Mean Developmental Delays 2Health News:Delivery Even a Bit Early May Mean Developmental Delays 3Health News:Researchers work at the frontiers of islet cell transplantation 2Health News:Researchers work at the frontiers of islet cell transplantation 3Health News:Cell-phone use not related to increased brain cancer risk 2Health News:Children in public housing play outdoors more 2
... a sterile nonpyrogenic, transparent viscoelastic solution of ... mg/mL of high molecular weight (greater than ... physiological saline. In the limit of zero ... (105 Pa s) at 25C, and the ...
Orbital Retractor, schepens Retractors, overall length:154mm....
... places fast and accurate visual ... Utilising standard computer hardware and ... with new testing and display ... integrated into a modern ophthalmic ...
... With a test capability extending to 80, ... a patient's visual field, allowing peripheral defects ... field to be explored. Practice Management Integration ... practice. With the Medmont Studio package the ...
Medicine Products: